IBRX280121C00003000
IBRX Jan 21 2028 3.00 Call
optionOPRA
EODOct 16, 2026
6.50USD-16.129%(-1.25)1Vol31,197OI
Loading…
Underlying
Underlying Price
$8.36
Type
Call
Strike
3
Expiration
Jan 21, 2028
DTE
458d
Moneyness
ITM
Intrinsic
$5.36
IBRX 3 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $7.05 | +2.32% | 2 | 112 |
| Oct 30, 2026 | 10d | $7.04 | -4.86% | 1 | 47 |
| Nov 6, 2026 | 17d | $6.50 | -19.45% | 2 | 30 |
| Nov 13, 2026 | 24d | $7.50 | +0.00% | 2 | 1 |
| Nov 20, 2026 | 31d | $6.41 | -7.90% | 21 | 61 |
| Nov 27, 2026 | 38d | $6.70 | -5.63% | 2 | 13 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $7.20 | +7.30% | 200 | 11,575 |
| Mar 19, 2027 | 150d | $5.73 | +8.11% | 10 | 709 |
| Apr 16, 2027 | 178d | $5.90 | +11.53% | 10 | 50 |
| May 21, 2027 | 213d | $5.84 | +16.80% | 1 | 5 |
| Aug 20, 2027 | 304d | — | — | 0 | 0 |
| Nov 19, 2027 | 395d | — | — | 0 | 0 |
| Jan 21, 2028 | 458d | $6.50 | -16.13% | 1 | 31,197 |
| Mar 17, 2028 | 514d | $8.50 | +41.67% | 1 | 945 |
| Jan 19, 2029 | 822d | $7.12 | -5.07% | 13 | 20 |
IBRX Nearby Strikes · Jan 21, 2028
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| .5 C | $8.93 | -4.18% | 2 | 128 | ITM |
| 1 C | $9.25 | -2.63% | 1 | 75 | ITM |
| 1.5 C | $8.25 | +18.36% | 5 | 38 | ITM |
| 2 C | $7.90 | -10.63% | 4 | 5,401 | ITM |
| 2.5 C | $7.40 | -7.50% | 6 | 15,793 | ITM |
| 3 C | $6.50 | -16.13% | 1 | 31,197 | ITM |
| 3.5 C | $7.10 | +1.87% | 10 | 27,275 | ITM |
| 4 C | $6.75 | -1.75% | 15 | 2,170 | ITM |
| 4.5 C | $6.65 | +2.78% | 2 | 380 | ITM |
| 5 C | $5.44 | -11.54% | 4,002 | 12,088 | ITM |
| 5.5 C | $5.21 | -12.14% | 2 | 3,514 | ITM |
| 7.5 C | $4.20 | -10.64% | 9,831 | 18,039 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.